This interim analysis of a 36-month post-marketing surveillance program reports real-world safety and effectiveness of teduglutide in 92 adults and children with short bowel syndrome in Japan (all patients who started treatment August 2021-August 2022). At 6 months, the overall mean change in parenteral nutrition dose was about -2402 mL/week, and 42.4% of patients (39/92) achieved at least a 20% reduction in parenteral-support volume. The paper notes teduglutide was approved in the USA and Europe in 2012 and in Japan in 2021 as the first GLP-2 analogue promoting intestinal adaptation.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.